CELH Stock Trades at Premium Value: Should You Buy, Hold or Sell?
Image Source: Zacks Investment Research
This premium valuation becomes even more striking when stacked against other major beverage players such as PepsiCo, Inc. PEP, Monster Beverage Corporation MNST, and The Coca-Cola Company KO. PepsiCo, Monster Beverage, and Coca-Cola are all trading at lower forward P/E ratios of 16.76X, 30.26X and 22.43X, respectively. Beyond valuation, recent stock performance further highlights Celsius Holdings' strong momentum. Over the past three months, CELH shares have rallied 24%, significantly outperforming the industry, sector and S&P 500's growth of 0.1%, 1.1%, and 19%, respectively. Among competitors, Monster Beverage stock gained 3%, while PepsiCo and Coca-Cola stocks lost 2.2% and 2.4%, respectively, in the same time frame. This impressive rally reflects bullish sentiment around CELH's growth trajectory but also contributes to the current valuation premium.
Image Source: Zacks Investment Research
Celsius Holdings continues to strengthen its position in the energy beverage market, driven by the core Celsius brand and the acquisition of Alani Nu, finalized on April 1, 2025. Together, Celsius Holdings and Alani Nu accounted for approximately 20% of the total dollar growth in the energy drink category during the first quarter of 2025. With complementary brand identities and strong consumer traction, the combined portfolio enhances Celsius Holdings' ability to capture a broader customer base and foster long-term brand loyalty.A focus on sugar-free, better-for-you products remains central to the company's strategy. As consumers increasingly seek healthier, ingredient-conscious beverages, Celsius Holdings is well-positioned to capitalize on this shift. Notably, sugar-free energy drinks contributed 86% of the total growth in the energy category during the first quarter, underscoring the relevance of CELH's product lineup.Innovation continues to fuel expansion. In the first quarter of 2025, the company introduced new Vibe and ESSENTIALS flavors, alongside the launch of CELSIUS HYDRATION, a product designed to tap into the growing $1.4 billion hydration powder market. These launches are driving deeper household penetration, supporting CELH's evolution from an occasional purchase to an everyday staple.Retail expansion also remains a key growth lever. The company has recently expanded its distribution through more than 1,800 Home Depot locations and 18,000 Subway restaurants, thereby increasing its presence in both foodservice and on-the-go consumption channels. This enhanced retail footprint sets the stage for continued growth across multiple sales platforms.
Reflecting positive sentiment around Celsius Holdings, the Zacks Consensus Estimate for earnings per share has seen upward revisions. Over the past 30 days, the consensus estimate has risen 1 cent each for the current quarter and the current financial year to 23 cents and 82 cents, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Image Source: Zacks Investment Research
While growth prospects remain robust, Celsius Holdings faces several near-term challenges that could pressure the stock. The energy drink market remains highly competitive, with established players like Monster Beverage and Red Bull maintaining an edge in shelf space, brand loyalty, and marketing scale. Both competitors continue to expand their product offerings and pursue aggressive pricing strategies. In this environment, Celsius Holdings must work harder to defend and grow market share, especially as the category evolves rapidly.In the first quarter of 2025, Celsius Holdings reported a 7% year-over-year revenue decline, primarily due to lower product velocity, changes in promotional timing, and difficult comparisons against the prior year's CELSIUS ESSENTIALS nationwide rollout. The revenue dip marks a slowdown in momentum compared to the company's strong historical performance. Rising operating expenses add another layer of risk. Selling, general, and administrative costs increased to $120.3 million in the first quarter from $99 million a year earlier, reflecting increased marketing, sales expansion, and costs related to the Alani Nu acquisition. Although these investments aim to fuel long-term expansion, they could pressure margins if revenue growth does not recover at the expected pace.
Celsius Holdings has achieved remarkable stock performance, driven by aggressive expansion, innovative product development, and the strategic acquisition of Alani Nu. The company's emphasis on sugar-free, functional beverages aligns with shifting consumer preferences, and an expanding retail footprint supports continued category growth. That said, the current valuation remains elevated compared to industry peers, raising questions about near-term upside. Recent revenue declines, higher operating expenses, and intensifying competition from brands like Monster and Red Bull add further challenges. Given these factors, long-term investors may consider holding the stock. Currently, CELH carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CocaCola Company (The) (KO) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Monster Beverage Corporation (MNST) : Free Stock Analysis Report
Celsius Holdings Inc. (CELH) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
US securities regulator announces AI task force
(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision
